A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Kura Oncology, Inc.
Baylor College of Medicine
Ipsen
Celgene
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)